Molloy Eamonn S, Calabrese Leonard H
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH 44195, USA.
Nat Rev Rheumatol. 2009 Aug;5(8):418-9. doi: 10.1038/nrrheum.2009.142.
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.
2009年4月，依法珠单抗因有报道称长期治疗与进行性多灶性白质脑病（PML）的发生有关联，而被撤出银屑病治疗市场。这一事件凸显出迫切需要提高对这种在接受慢性炎症性疾病免疫抑制治疗患者中可能致命疾病的筛查、诊断及治疗的认识并开展研究。
